Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PANOBINOSTAT for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where PANOBINOSTAT was used for Neoplasm malignant.

Most Reported Side Effects for PANOBINOSTAT

Side Effect Reports % Deaths Hosp.
Diarrhoea 368 20.2% 76 124
Plasma cell myeloma 279 15.3% 170 80
Platelet count decreased 192 10.6% 72 90
Death 190 10.4% 189 17
Malignant neoplasm progression 166 9.1% 104 61
Fatigue 162 8.9% 28 46
Nausea 154 8.5% 44 63
Thrombocytopenia 141 7.8% 30 60
Off label use 112 6.2% 37 9
Vomiting 109 6.0% 20 60
Drug ineffective 105 5.8% 46 18
Pneumonia 99 5.4% 39 69
Pyrexia 98 5.4% 40 65
Anaemia 95 5.2% 39 49
White blood cell count decreased 83 4.6% 35 49

Other Indications for PANOBINOSTAT

Plasma cell myeloma (1,262) Product used for unknown indication (244) Plasma cell myeloma refractory (49) Acute myeloid leukaemia (33) Brain stem glioma (15) Plasmacytoma (14) Hodgkin's disease (13) Plasma cell leukaemia (12) Glioma (10) Graft versus host disease (10)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

PANOBINOSTAT Full Profile All Neoplasm malignant Drugs PANOBINOSTAT Demographics PANOBINOSTAT Timeline